Please wait a minute...
Acta Metall Sin  2017, Vol. 53 Issue (10): 1153-1167    DOI: 10.11900/0412.1961.2017.00319
Orginal Article Current Issue | Archive | Adv Search |
Research Progress in Bioresorbable Magnesium Scaffolds
Tingfei XI1,2(), Lina WEI1,3, Jing LIU2, Xiaoli LIU4, Zhen ZHEN1, Yufeng ZHENG5
1 Shenzhen Institute, Peking University, Shenzhen 518057, China
2 Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China
3 National Institute for Food and Drug Control, Beijing 100050, China
4 College of Materials Science and Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, China
5 Department of Materials Science and Engineering, College of Engineering, Peking University, Beijing 100871, China
Download:  HTML  PDF(9003KB) 
Export:  BibTeX | EndNote (RIS)      

Because the bioresorbable scaffold (BRS) could overcome the difficulties caused by traditional nondegradable stents including chronic inflammation, late stent thrombosis, and long-term antiplatelet therapy, BRS is the research focus of interventional medical engineering. Because of both the high supporting strength and bioresorbable feature, the bioresorbable magnesium scaffold (BMS) is the research focus of BRS. In this paper, development process of Biotronik serial magnesium stents along with research progress of our domestic AZ31, JDBM and MgZnYNd stents is reviewed. According to the results of extensive in vitro and in vivo studies, BMS is safe and effective in vivo although its degradation rate is faster than our expectation. Through developing novel alloy system and improving stents' structure, the performance of BMS will be better and it will play more important role on the therapy of cardiovascular disease.

Key words:  bioresorbable magnesium scaffold      WE43 magnesium alloy      JDBM magnesium alloy      MgZnYNd magnesium alloy     
Received:  28 July 2017     
ZTFLH:  R318.08  
Fund: Supported by Natural Science Foundation of Guangdong Province (Nos.2016A030310245 and 2016A030310244), China Postdoctoral Science Foundation (No.2016M591017) and Shenzhen Fundamental Research (No.JCYJ20160427170611414)

Cite this article: 

Tingfei XI, Lina WEI, Jing LIU, Xiaoli LIU, Zhen ZHEN, Yufeng ZHENG. Research Progress in Bioresorbable Magnesium Scaffolds. Acta Metall Sin, 2017, 53(10): 1153-1167.

URL:     OR

Fig.1  Schematic cross-sectional profile of magnesium scaffolds struts of uncoated, non-eluting, AMS-1 with 80 μm×165 μm (a); DREAMS 1st generation (DREAMS 1G) with 130 μm×120 μm struts (b) and DREAMS 2nd generation (2G) with 150 μm×140 μm struts (c)[14]
Animal/clinical Stent type Implantation site Follow up Main result Ref.
study (quantity)
Animal Lekton Coronary artery 4 and 12 Homogenous and rapid endothelialization [15]
(Pig, 33) Magic? Weeks of the Mg alloy stent
Animal Lekton Coronary artery 3 d, 1 and Mg alloy stents are safe and are associated with [16]
(Pig, 17) Magic? 3 months less neointima formation; however, reduced
neointima did not result in larger lumen
Single case Lekton Left pulmonary 3 d, 1 and Mg alloy stents are safe even in pediatric [17]
Magic? artery 4 months patients; bioabsorbable stents with different
diameters may be more helpful in vessel
stenosis diseases
Single case Lekton Aorta 3 months Mg alloy stents are safe and efficacy [18]
Single case Lekton Aortopulmonary 4 months Mg alloy stents are safe and efficacy in [19]
Magic? collateral children previously deemed unsuitable for
stent placement
Clinical (20) Lekton Infrapopliteal 1 and 3 Mg alloy stents are safe and efficacy in the [20]
Magic? vessels months treatment of below-knee lesions after
3 months based on the primary clinical
patency and limb salvage rates
Clinical (117) Lekton Infrapopliteal 1 and 6 Mg alloy stents are safe, but it did not demonstrate [21]
Magic? vessels months efficacy in long-term patency over standard
PTA1 in the infrapopliteal vessels
Clinical (63) Lekton Coronary artery 4, 6 and Mg alloy stents can achieve an immediate [3]
Magic? 12 months angiographic result similar to the result of
other metal stents and can be safely degraded
after 4 months
Clinical (63) Lekton Coronary artery 4, 12 and IVUS2 imaging supports the safety profile of Mg [22]
Magic? 28 months alloy stents with degradation at 4 months and
maintains durability of the results without any
early or late adverse findings
Clinical (63) DREAMS Coronary artery 1, 6 and DREAMS (Mg alloy stents) is safe and efficacy, [4]
12 months promising clinical and angiographic performance
results up to 12 months
Clinical (63) DREAMS Coronary artery 24 and DREAMS is safe and efficacy with no death and [23]
36 months no scaffold thrombosis up to 3 years; stents could
be absorbed completely within 6 months
Clinical (123) DREAMS Coronary artery 6 and 12 Implantation of the DREAMS 2G device in [5]
2G months de-novo coronary lesions is feasible, with
favorable safety and performance outcomes at
6 months. This novel absorbable metal scaffold
could be an alternative to absorbable polymeric
scaffolds for treatment of obstructive
coronary disease
Table 1  Animal and clinical studies of Biotronik absorbable Mg-alloy stents[3-5,15-23]
Fig.2  Low (a, c) and high (b, d) magnified representative photomicrographs of hematoxylin-eosin (HE) stained sections of porcine coronary arteries 28 d after stainless steel stent (a, b) and magnesium alloy stent (c, d) implantation[16]
Fig.3  Surface morphologies (a, c, e) and the schematics (b, d, f) of the corresponding degradation mechanism of JDBM (a, b), WE43 (c, d) and AZ31 (e, f) alloys[32]
Fig.4  The in vivo aortic angiographies showing no acute and late thrombogenesis as well as in-stent restenosis in the JDBM-2 (a) and 316L stainless steel (c) stents after stenting for 1 month, 2 months, 4 months and 6 months (from left to right). The corresponding follow-up IVUS images illustrating the longitudinal reconstruction of the abdominal aorta after the JDBM-2 (b) and 316L stainless steel (d) stents implantation[33]
Fig.5  HE staining images of the stented arteries showing compromised foreign body reaction and neointimal coverage on the JDBM-2 struts in the period of 1 month (a), 2 months (b), 4 months (c) and 6 months (d) implantation (Inset in each image showing detailed view of the stented artery)[33]
Fig.6  Cell viabilities cultured on bare MgZnYNd, 2%PLGA-APTES-MgZnYNd, 4%PLGA-APTES-MgZnYNd, and 4%PLGA-MgZnYNd samples over 5 d of incubation by the CCK-8 assay; DMEM with serum worked as negative control, DMEM with 10% dimethyl sulfoxide as positive control. Data presented were statistically analyzed by using a one-way ANOVA, *** represents p<0.001, * represents p<0.05[36]
a) VSMC (b) EA. hy926
Fig.7  Microscope (a~c) and SEM (d, e) images of MgZnYNd stent: (a) before crimping onto balloon, (b) after crimping onto balloon, (c, d) after expanding at nominal pressure (6 bar), the outer diameter under the three conditions were (2.00±0.03) mm, (1.58±0.04) mm and (3.00±0.06) mm (n=6), respectively, (e) integrity of PLGA coating was maintained after plastic deformation with no obvious peeling detected, while visible regional nanosized cracking (with no exposure of the underlying strut) was observed as a result of stress accommodation only in locations of larger plastic deformation, (f) flexibility test was performed through “three-point blending” method, (g) self-designed simulated vascular channel model equipped with 6F catheter (internal diameter: 1.98 mm) according to the guidance in ASTM-F2394-07 to test stent compliance, (h) stents conducting push and withdrawal process in the channel model, and (i) the postexperiment stent image[36]
Fig.8  CAG (a), OCT (b) and H&E staining images (c) after MgZnYNd stent and control group BuMATM stent implantation for a period of six months (The red arrows in Figs.8a and b signify the outline and remnants of the stent struts of MgZnYNd stent, and the enlarged insets in Fig.8c showed the more detailed morphologies)[36]
Implantation duration Stent type RLD MLD DSR
month mm mm %
1 MgZnYNd (n=3) 2.62±0.20 2.09±0.33 20.67±9.07
BuMATM (n=3) 2.59±0.65 2.15±0.41 15.67±5.86
p value 0.67 0.88 0.56
3 MgZnYNd (n=3) 2.42±0.16 2.03±0.80 15.67±8.14
BuMATM (n=3) 2.03±0.18 1.51±0.13 15.67±5.86
p value 0.22 0.04 0.11
6 MgZnYNd (n=3) 2.75±0.26 2.30±0.49 15.33±22.23
BuMATM (n=3) 2.65±0.80 2.05±0.31 22.33±14.15
p value 0.11 0.62 0.13
Table 2  Coronary angiography results of MgZnYNd stent and BuMATM stent post-implantation for a period of 1, 3 and 6 months, respectively[36]
Implantation Stent type Stent length DRVA PRVA MLA MSA
duration / month mm mm2 mm2 mm2 mm2
1 MgZnYNd (n=3) 14.30±1.27 2.56±2.87 2.72±2.80 2.02±1.84 2.62±1.94
BuMATM (n=3) 14.70±2.08 2.84±0.83 3.68±0.93 2.49±0.37 4.97±1.10
3 MgZnYNd (n=3) 14.80±0.97 4.51±1.37 6.36±2.16 3.87±1.85 5.52±2.10
BuMATM (n=3) 14.25±4.45 2.58±0.19 4.09±1.24 2.32±0.05 5.22±0.61
6 MgZnYNd (n=3) 14.13±0.95 3.92±0.79 3.94±0.78 2.93±0.58 4.52±1.08
BuMATM (n=3) 14.40±2.78 5.58±2.43 5.89±1.66 3.03±1.09 6.03±1.90
Table 3  Optical coherence tomography results of MgZnYNd stent and BuMATM stent post-implantation for a period of 1, 3, and 6 months, respectively[36]
[1] Serruys P W, Ormiston J A, Onuma Y, et al.A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods[J]. Lancet, 2009, 373: 897
[2] Gogas B D, Serruys P W, Diletti R, et al.Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: A virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial[J]. JACC Cardiovasc. Interv., 2012, 5: 656
[3] Erbel R, Di Mario C, Bartunek J, et al.Three-year clinical data of the biosolve-I study with the paclitaxel-eluting bioabsorbable magnesium scaffold (Dreams) and multi-modality imaging analysis[J]. Circulation, 2013, 128(22S): 11264
[4] Haude M, Erbel R, Erne P, et al.Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial[J]. Lancet, 2013, 381: 836
[5] Haude M, Ince H, Abizaid A, et al.Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial[J]. Lancet, 2016, 387: 31
[6] Eberhart R C, Su S H, Nguyen K T, et al.Bioresorbable polymeric stents: Current status and future promise[J]. J Biomater. Sci. Polym. Ed., 2003, 14: 299
[7] Lincoff A M, Furst J G, Ellis S G, et al.Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model[J]. J. Am. Coll. Cardiol., 1997, 29: 808
[8] Waksman R.Update on bioabsorbable stents: From bench to clinical[J]. J. Interv. Cardiol., 2006, 19: 414
[9] Erne P, Schier M, Resink T J.The road to bioabsorbable stents: Reaching clinical reality?[J]. Cardiovasc. Inter. Rad., 2006, 29: 11
[10] Smith L F, Heagerty A M, Bing R F, et al.Intravenous infusion of magnesium-sulfate after acute myocardial-infarction: Effects on arrhythmias and mortality[J]. Int. J. Cardiol., 1986, 12: 175
[11] Christensen C W, Rieder M A, Silverstein E L, et al.Magnesium-sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model[J]. Circulation, 1995, 92: 2617
[12] Rukshin V, Azarbal B, Shah P K, et al.Intravenous magnesium in experimental stent thrombosis in swine[J]. Arterioscl. Throm. Vas., 2001, 21: 1544
[13] Heublein B, Rohde R, Kaese V, et al.Biocorrosion of magnesium alloys: A new principle in cardiovascular implant technology?[J]. Heart, 2003, 89: 651
[14] Campos C M, Muramatsu T, Iqbal J, et al.Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease[J]. Int. J. Mol. Sci., 2013, 14: 24492
[15] Di Mario C, Griffiths H, Goktekin O, et al.Drug-eluting bioabsorbable magnesium stent[J]. J. Interv. Cardiol., 2004, 17: 391
[16] Waksman R, Pakala R, Kuchulakanti P K, et al.Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries[J]. Catheter Cardiovasc. Interv., 2006, 68: 607
[17] Zartner P, Cesnjevar R, Singer H, et al.First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby[J]. Catheter Cardio. Interv., 2005, 66: 590
[18] Schranz D, Zartner P, Michel-Behnke I, et al.Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newborn[J]. Catheter Cardio. Int., 2006, 67: 671
[19] McMahon C J, Oslizlok P, Walsh K P. Early restenosis following biodegradable stent implantation in an aortopulmonary collateral of a patient with pulmonary atresia and hypoplastic pulmonary arteries[J]. Catheter Cardio. Int., 2007, 69: 735
[20] Peeters P, Bosiers M, Verbist J, et al.Preliminary results after application of absorbable metal stents in patients with critical limb ischemia[J]. J. Endovasc. Ther., 2005, 12: 1
[21] Bosiers M.AMS INSIGHT—absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis[J]. Cardiovasc. Interv. Radiol., 2009, 32: 424
[22] Waksman R, Erbel R, Di Mario C, et al.Early-and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries[J]. Jacc-Cardiovasc. Int., 2009, 2: 312
[23] Haude M, Erhel R, Erne P, et al.Three-year clinical data of the biosolve-I study with the paclitaxel-eluting bioabsorbable magnesium scaffold (Dreams) and multi-modality imaging analysis[J]. Circulation, 2013, 128(22S): 11264
[24] Haude M, Erbel R, Erne P, et al.TCT-38 two-year clinical data of cohort 1 and multi-modality imaging resuts up to 1-year follow-up of the BIOSOLVE-I study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS)[J]. J. Am. Coll. Cardiol., 2012, 60: B11
[25] Haude M, Ince H, Abizaid A, et al.Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial[J]. Eur. Heart J., 2016, 37: 2701
[26] Tan L L, Wang Q, Geng F, et al.Preparation and characterization of Ca-P coating on AZ31 magnesium alloy[J]. Trans. Nonferrous Met. Soc. China, 2010, 20: S648
[27] Lu Y J, Wan P, Zhang B C, et al.Research on the corrosion resistance and formation of double-layer calcium phosphate coating on AZ31 obtained at varied temperatures[J]. Mater. Sci. Eng., 2014, C43: 264
[28] Qiu X, Wan P, Tan L L, et al.Preliminary research on a novel bioactive silicon doped calcium phosphate coating on AZ31 magnesium alloy via electrodeposition[J]. Mater. Sci. Eng., 2014, C36: 65
[29] Li H W, Xu K, Yang K, et al.The degradation performance of AZ31 bioabsorbable magnesium alloy stent implanted in the abdominal aorta of rabbits[J]. J. Interv. Radiol., 2010, 19: 315(李海伟, 徐克, 杨柯等. 可降解AZ31镁合金支架在兔腹主动脉的降解性能研究[J]. 介入放射学杂志, 2010, 19: 315)
[30] Li J L, Zheng F, Qiu X, et al.Finite element analyses for optimization design of biodegradable magnesium alloy stent[J]. Mater. Sci. Eng., 2014, C42: 705
[31] Yuan G Y, Zhang X B, Niu J L, et al.Research progress of new type of degradable biomedical magnesium alloys JDBM[J]. Chin. J. Nonferrous Met., 2011, 21: 2476(袁广银, 章晓波, 牛佳林等. 新型可降解生物医用镁合金JDBM的研究进展[J]. 中国有色金属学报, 2011, 21: 2476)
[32] Mao L, Shen L, Niu J L, et al.Nanophasic biodegradation enhances the durability and biocompatibility of magnesium alloys for the next-generation vascular stents[J]. Nanoscale, 2013, 5: 9517
[33] Mao L, Shen L, Chen J H, et al.A promising biodegradable magnesium alloy suitable for clinical vascular stent application[J]. Sci. Rep., 2017, 7: 46343
[34] Guan S K, Wang J, Wang L G, et al.The Mg-Zn-Y-Nd magnesium alloy for biodegradable vascular stents and its preparation method [P]. Chin Pat, 201110043303.8, 2011(关绍康, 王俊, 王利国等. 一种可生物降解血管支架用Mg-Zn-Y-Nd镁合金及其制备方法 [P]. 中国专利, 201110043303.8, 2011)
[35] Xi T F, Liu J, Wang M, et al.One kind of surface coating which can reduce the degradation rate of biodegradable Magnesium alloy vascular stents and its preparation method [P]. Chin Pat, 201410200367.8, 2014(奚廷斐, 刘婧, 王敏等. 降低可全降解镁合金血管支架降解速率的表面涂层制备方法 [P]. 中国专利, 201410200367.8, 2014)
[36] Liu J, Zheng B, Wang P, et al.Enhanced in vitro and in vivo performance of Mg-Zn-Y-Nd alloy achieved with APTES pretreatment for drug-eluting vascular stent application[J]. ACS Appl. Mater. Interfaces, 2016, 8: 17842
[37] Joner M, Finn A V, Farb A, et al.Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk[J]. J. Am. Coll. Cardiol., 2006, 48: 193
[38] Virmani R, Guagliumi G, Farb A, et al.Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious?[J]. Circulation, 2004, 109: 701
[39] Kotani J, Awata M, Nanto S, et al.Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings[J]. J. Am. Coll. Cardiol., 2006, 47: 2108
[40] Liu J, Xi T F.Enhanced anti-corrosion ability and biocompatibility of PLGA coatings on MgZnYNd alloy by BTSE-APTES pre-treatment for cardiovascular stent[J]. J. Mater. Sci. Technol., 2016, 32: 845
[41] Liu J, Liu X L, Xi T F, et al.A novel pseudo-protein-based biodegradable coating for magnesium substrates: In vitro corrosion phenomena and cytocompatibility[J]. J. Mater. Chem., 2015, 3B: 878
[1] Zheng MA, Xi LU, Ming GAO, Lili TAN, Ke YANG. Effect of Crevice Corrosion on the Degradation Rate ofFe-30Mn-1C Alloy[J]. 金属学报, 2018, 54(7): 1010-1018.
[2] Muqin LI, Haitao YAO, Fanghong WEI, Mingda LIU, Zan WANG, Shuhao PENG. The Microstructure and in Vivo and in Vitro Property of Multi-Component Composite Films on the Biomedical Pure Magnesium Surface[J]. 金属学报, 2017, 53(10): 1337-1346.
[3] Yibin REN, Haochuan ZHAO, Ke YANG. Study on Lightweight Design and Biomechanical Property of High Nitrogen Nickel Free Stainless Steel Plate: Effect of Thickness Thinning[J]. 金属学报, 2017, 53(10): 1331-1336.
[4] Yufeng ZHENG, Hongtao YANG. Research Progress in Biodegradable Metals forStent Application[J]. 金属学报, 2017, 53(10): 1227-1237.
[5] Yibin REN, Jun LI, Qingchuan WANG, Ke YANG. A Review: Research on MR-Compatible Alloys in MRI[J]. 金属学报, 2017, 53(10): 1323-1330.
[6] Cong PENG, Shuyuan ZHANG, Ling REN, Ke YANG. Effect of Cooling Rate on Microstructure and Properties ofa Cu-Containing Titanium Alloy[J]. 金属学报, 2017, 53(10): 1377-1384.
[7] Ying ZHAO, Lilan ZENG, Tao LIANG. Development in Biocompatibility of Biodegradable Magnesium-Based Metals[J]. 金属学报, 2017, 53(10): 1181-1196.
[8] Jiahui DONG, Lili TAN, Ke YANG. Research of Biodegradable Mg-Based Metals as Bone Graft Substitutes[J]. 金属学报, 2017, 53(10): 1197-1206.
[9] Zhentao YU, Sen YU, Jun CHENG, Xiqun MA. Development and Application of Novel Biomedical Titanium Alloy Materials[J]. 金属学报, 2017, 53(10): 1238-1264.
[10] Xiao LIN, Jun GE, Shuilin WU, Baohua LIU, Huilin YANG, Lei YANG. Advances in Metallic Biomaterials with both Osteogenic and Anti-Infection Properties[J]. 金属学报, 2017, 53(10): 1284-1302.
[11] Dewei ZHAO, Junlei LI. Fabrication of the Porous Tantalum and Its Current Status Used as Orthopedics Implants Materials[J]. 金属学报, 2017, 53(10): 1303-1310.
[12] Lili TAN, Junxiu CHEN, Xiaoming YU, Ke YANG. Recent Advances on Biodegradable MgYREZrMagnesium Alloy[J]. 金属学报, 2017, 53(10): 1207-1214.
[13] . Bone Induction of a Biodegradable Magnesium Alloy[J]. 金属学报, 2008, 44(9): 1035-1041 .
[14] GUI Lin. Synthesis of Cobalt Ferrite Nanoarticles in High Static Magnetic Field by Coprecipitation-Phase Transform way[J]. 金属学报, 2007, 43(5): 529-533 .
[15] Yang Huajuan; Yang Ke; Zhang Bingchun. STUDY OF IN VITRO ANTICOAGULANT PROPERTY OF THE La ADDED MEDICAL 316L STAINLESS STEEL[J]. 金属学报, 2006, 42(9): 959-964 .
No Suggested Reading articles found!